Which gene mutations does the lung adenocarcinoma targeted drug brigatinib target?

The lung adenocarcinoma targeted drug Brigatinib (Brigatinib) is a lung cancer treatment drug that targets specific gene mutations. In the treatment of lung adenocarcinoma, brigatinib mainly targets mutations in the anaplastic lymphoma kinase (ALK) gene.

The main function of brigatinib is to inhibit the mutation of ALK gene. ALKThe gene can be rearranged or mutated in some patients with lung adenocarcinoma, leading to abnormal proliferation and spread of cancer cells. Brigatinib binds to ALK kinase and blocks its signaling pathway, thereby inhibiting the growth and metastasis of tumor cells. This drug has a high efficacy for patients with ALK positive lung adenocarcinoma and can significantly extend the progression-free survival of patients.

Although the overall incidence of ALK gene mutations in lung adenocarcinoma is not high, accounting for 3-5%, this mutation type is more common in non-Asian, young, non-smoking or light smokers with lung adenocarcinoma. For these specific populations, brigatinib offers an effective treatment option.

Clinical studies have shown that brigatinib has shown significant efficacy in the treatment of ALK-positive lung adenocarcinoma patients. In a clinical trial, brigatinib was shown to significantly extend progression-free survival and achieve tumor shrinkage in most patients. In addition, brigatinib has also demonstrated good ability to penetrate the blood-brain barrier and has certain efficacy in patients with brain metastases.

When using brigatinib, doctors will develop a personalized treatment plan based on the patient's specific conditions and regularly monitor the drug's efficacy and side effects. Common side effects include nausea, diarrhea, fatigue, etc., but they can usually be alleviated by adjusting the drug dosage or providing corresponding supportive care.

References:

https://www.cancerresearchuk.org/about-cancer/treatment/drugs/brigatinib